| 1 |
35603651 | [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways]. | 2022 May |
3 |
| 2 |
33452624 | Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review. | 2021 Jan 16 |
1 |
| 3 |
34461124 | PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia. | 2021 Nov 5 |
2 |
| 4 |
30959969 | Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling. | 2019 Apr 7 |
3 |
| 5 |
29165716 | Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. | 2018 May 1 |
1 |
| 6 |
26206305 | Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. | 2015 Dec 1 |
1 |
| 7 |
26359452 | Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. | 2015 Oct 15 |
1 |
| 8 |
23468082 | Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. | 2013 May |
2 |